Purpose: This phase II study was undertaken to assess objective response, toxicity, tumor marker response, and pharmacodynamics of bortezomib in patients with metastatic neuroendocrine (carcinoid and islet cell) tumors.
INTRODUCTION
Because of the pivotal role of the proteasome in controlling key cellular processes, the proteasome has emerged as an attractive novel target for the development of anticancer therapy (1) . The 26S proteasome is an ATP-dependent multicatalytic protease that is central to the ubiquitin-proteasome-degradative pathway. The 26S proteasome acts as a housekeeper to eliminate damaged or misfolded proteins. In addition, many regulatory proteins governing the cell cycle, transcription factor activation, apoptosis, and cell trafficking, are the substrates for proteasomemediated degradation (1) . The proteasome plays a significant role in degradation of cyclin-dependent kinase inhibitors (p21, p27; refs. 2, 3) and tumor suppressor (p53; ref. 4) proteins that are required for cell cycle arrest. The proteasome is also required for activation of transcription factor nuclear factor-B by degradation of its inhibitory protein inhibitor of nuclear factor-B (5). Nuclear factor-B is necessary, in part, to maintain cell viability through transcription of inhibitors of apoptosis in response to stress or cytotoxic agents. Nuclear factor-B has also been implicated in controlling gene expression of endothelial cell surface adhesion molecules such as intercellular adhesion molecule 1, vascular cell adhesion molecule, and E-selectin (6) , which are involved in tumor metastasis and angiogenesis. Furthermore, the proteasome is implicated in in vivo angiogenesis, a phenomenon essential for tumor growth and metastasis (7) .
Bortezomib [Velcade (Millennium Pharmaceuticals, Inc., Cambridge, MA), previously known as PS-341] is a dipeptidyl boronic acid that is a specific, potent and reversible inhibitor of the 26S proteasome. Preclinical work revealed significant antitumor activity of bortezomib in vitro and in vivo. In the cell line screen of the National Cancer Institute, bortezomib demonstrated a unique pattern of growth inhibitory and cytotoxic activity against a broad range of solid tumors (8) . Bortezomib also significantly reduced tumor volumes in several murine and human tumor xenograft models including the Lewis lung, HT-29 human colon, PC-3 human prostate, squamous cell carcinoma, and pancreatic cancer (9 -13) . The initial dose and schedule of bortezomib for phase I clinical trials was chosen based on the acute and multiple dose toxicity studies performed on rodents and primates (14) . Preclinical studies in animals showed that bortezomib was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection. Therefore, a sensitive, accurate and reproducible ex vivo 20S proteasome inhibition assay to monitor bortezomib activity in whole blood was developed (15) . Several phase I and/or II clinical trials done to date showed that the target proteasome inhibition of ϳ70% can be achieved in cancer patients with a reasonable safety profile. Moreover, complete responses, partial responses, or minor responses were observed in the variety of solid tumors and hematologic malignancies (16 -20) . Bortezomib was recently approved by the Food and Drug Administration for its use in the patients with refractory or relapsed multiple myeloma.
Carcinoid and islet cell tumors are generally classified at the less-aggressive end of the spectrum of neuroendocrine tumors. They are thought to derive from enterochromaffin cells, which are distributed throughout the gastrointestinal and respiratory system. Although plasma chromogranin A and 24-hour urine for 5-hydroxy indole acetic acid are known prognostic markers for survival in patients with carcinoid tumors, the role of other tumor markers is not well described (21, 22) . Although local or locoregional carcinoid or islet cell tumors are surgically manageable, metastatic disease is present in ϳ50% of patients at the time of diagnosis, and the overall 5-year survival for patients with distant metastasis is only 22%. Somatostatin analogues, IFN-␣ or hepatic artery chemoembolization provide good palliation of the symptoms of carcinoid syndrome associated with such tumors. However, no systemic therapy has been shown to consistently elicit tumor responses and prolong survival. The ineffectiveness of systemic chemotherapy in metastatic neuroendocrine tumors may relate to their unique biological features such as slow growth pattern or hypervascularity.
Preclinical in vitro and in vivo work suggests that bortezomib has antitumor activity in a broad spectrum of solid tumors, including the PC-12 neuroendocrine (pheochromocytoma) tumor cell line (23) . Although primarily targeting the proteasome pathway, bortezomib has been shown to affect key proteins involved in cell cycle regulation, angiogenesis, and apoptosis. On the basis of this and the unique antitumor mechanisms of bortezomib, we hypothesize that it may have clinical activity in metastatic carcinoid and islet cell tumors. We thus conducted a phase II clinical trial in patients with metastatic carcinoid and islet cell tumors. On the basis of toxicity and pharmacodynamic data available from initial phase I clinical trials in solid tumor and hematologic malignancies, the dose of 1.5 mg/m 2 administered as an i.v. bolus on days 1, 4, 8, and 11 every 21 days was considered optimal for our trial. We report the results of the first prospective phase II study of bortezomib in patients with metastatic neuroendocrine tumors.
PATIENTS AND METHODS
Patient Selection. Eligibility criteria included histologically confirmed well-differentiated neuroendocrine carcinoma; metastatic and measurable disease; no more than one prior systemic chemotherapy regimen; no IFN-␣, systemic chemotherapy, or radiation therapy within the past 4 weeks; no hepatic artery chemoembolization within the past 12 weeks; age Ն 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; life expectancy Ն 6 months; and adequate organ functions: total bilirubin Յ 1.5 mg/dL, aspartate aminotransferase/ alanine aminotransferase Յ 2.5ϫ upper limit of normal, absolute neutrophil count Ն 1500/L, platelet count Ն 100,000/L, and serum creatinine of Յ1.5 mg/dL. The standard dose (10 to 40 mg every 3 to 4 weeks) of intramuscular long-acting octreotide [Sandostatin LAR (Novartis Pharmaceuticals Co., East Hanover, NJ)] was permitted for the control of carcinoid syndrome symptoms provided that the dose was stable for 3 months before study entry. Exclusion criteria were pregnancy, breastfeeding, and uncontrolled intercurrent illness.
Study Design. Bortezomib was administered as an i.v. bolus at a dose of 1.5 mg/m 2 on days 1, 4, 8, and 11 every 21 days. Antiemetic therapy or growth factor support was not used on a prophylactic basis. Therapy was given for a total of 24 weeks unless patients met one of the following criteria: progressive disease; unacceptable adverse event; off of study drug for Ͼ2 weeks; or patient withdrawal from the study. Patients were maintained at the full dose of 1.5 mg/m 2 unless patients had grade 3 or 4 adverse event. In case of grade 3 or 4 adverse event, treatment was withheld for 1 week. Upon reevaluation, patients who showed a partial (improvement to grade 1 or 2 adverse event) or a full resolution were started on bortezomib at the reduced dose of 1.0 mg/m 2 that was escalated to 1.3 mg/m 2 after 1 week and to 1.5 mg/m 2 after the second week as tolerated. The patients with persistent grade 3 or 4 adverse event were taken off of the protocol.
History, physical examination, complete blood count, and serum chemistry were obtained within 14 days before initiation of therapy and within 2 to 4 weeks after the last dose of bortezomib (posttreatment). Baseline tumor measurements were performed with computed tomography scan within 4 weeks before initiation of therapy and repeated every 12 weeks during study and at the posttreatment visit. In addition, patients had a history and physical examination performed every 6 weeks and had complete blood count, serum chemistries, and adverse event evaluation performed once a week during their treatment weeks (week 1, 2, 4, 5, and so on). Objective response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and toxicity was assessed according to National Cancer Institute Common Toxicity Criteria, version 2.0 (24). Tumor Marker Studies. Serum tumor markers (pancreastatin, gastrin, calcitonin, pancreatic polypeptide, vasoactive intestinal peptide, neurotensin, substance-P, gastrin-releasing peptide, glucagon, somatostatin, and serotonin) and 24-hour urine for 5-hydroxy indole acetic acid were obtained within 14 days before initiation of therapy every 12 weeks during therapy and within 2 to 4 weeks posttreatment.
Pharmacodynamic Studies. We used an ex vivo 20S proteasome inhibition assay to monitor bortezomib activity in whole blood using the previously described method (15) . This fluorogenic kinetic assay consisted of measuring proteasome activity at chymotryptic and tryptic sites within the 20S core of the proteasome and determining the degree of inhibition conferred by bortezomib. Using the ratio of these chymotryptic: tryptic activities and the catalytic mechanism of the proteasome, percentage of inhibition was calculated compared with predose whole blood obtained from the same patient.
Blood samples were collected at 0 hour (just before administration of bortezomib), 1 hour, and 24 hours after bortezomib on days 1 and 4 of the first course of therapy. For each time point, 8-mL of blood were collected in one heparinized green top tube, immediately placed on ice, and then frozen at Ϫ70°C. Batched samples were shipped on dry ice to Millennium Pharmaceuticals, Inc., for performing an assay. On the basis of the preclinical efficacy and toxicity studies, a target level of ϳ70% proteasome inhibition was considered optimal.
Statistical Considerations. For this phase II study, the minimax two-stage design of Simon was chosen, resulting in a trial with a decision to proceed to the second stage based on efficacy seen in the first 16 patients. Bortezomib was to be considered ineffective or uninteresting if the true response probability was Ͻ10% (p 0 ). The regimen was to be worthy of further study if the true response probability or target response rate was Ն30% (p 1 ). These figures resulted in a two-stage design of 16 and 25 patients, with an ␣ of 0.10 and ␤ of 0.10. If one or no responses were seen in the first 16 patients, the study was to be terminated early, and this regimen was deemed ineffective for this patient population. If two or more patients respond in the first 16, an additional 9 patients were to be treated for a total of 25.
The primary end point was to assess the objective response (partial remission or complete remission) of bortezomib in metastatic carcinoid and islet cell tumors. Stable disease was not considered an objective response to therapy given the relatively slow-growing nature of these cancers and due to a single-arm study design. Patients who had stable disease were taken off from the protocol at 24 weeks of therapy. Secondary end points were to assess the toxicity of bortezomib in patients with metastatic neuroendocrine tumors, to assess tumor marker response, and to evaluate pharmacodynamics of bortezomib by ex vivo 20S proteasome inhibition assay.
RESULTS
Patients. After obtaining informed consent, 16 patients with metastatic neuroendocrine tumor were enrolled on to the Institutional Review Board-approved phase II study at The Ohio State University (n ϭ 14) and at University of Chicago (n ϭ 2) between May 2001 and December 2001. Patient characteristics are outlined in Table 1 . A majority of patients (n ϭ 12; 75%) had carcinoid tumors, whereas the rest (n ϭ 4, 25%) had islet cell tumors. Of the four patients with islet cell tumors, one patient had symptoms of diarrhea related to carcinoid syndrome, whereas the rest of the patients had no symptoms associated with abnormally high hormone production (pancreatic polypeptide, gastrin, glucagon, or calcitonin) related to their islet cell tumors.
Treatment Administered. If the best response achieved was stable disease, treatment with bortezomib was continued for up to 24 weeks (32 doses). All 16 patients received median of 15 doses (range, 1 to 32 doses), with a median cumulative total dose of 21.8 (range, 1.5 to 48) mg/m 2 . Of the total 264 doses given in the study, 42 doses in seven patients were given at the reduced doses per protocol guidelines because of grade 3 adverse events [neutropenia (n ϭ 2), peripheral neuropathy (n ϭ 2), ileus (n ϭ 2), and thrombocytopenia (n ϭ 1)] or recurrent grade 2 vomiting. The median duration of therapy for all patients was 12 weeks (range, 0.5 to 24 weeks) and only 4 of 16 patients (25%) completed 24 weeks of therapy. The reasons for leaving the study before 24 weeks of planned therapy in the 12 patients included progressive disease (n ϭ 3), persistent grade 3 adverse events [peripheral neuropathy (n ϭ 2), diarrhea (n ϭ 1), fatigue (n ϭ 1)], and patient withdrawal [grade 3 hypertension/ atrial fibrillation (n ϭ 1); grade 2 nausea (n ϭ 1), vomiting (n ϭ 1) or seizure (n ϭ 1); and social reason (n ϭ 1)] (Fig. 1) .
Objective Response. All 16 patients were considered evaluable for response in an intent-to-treat analysis. No patients achieved a partial response or a complete response. Stable disease was noted in 11 of 16 patients (69%) at the median evaluation time of 12 weeks (range, 3 to 24 weeks) after the start of therapy. Five patients (31%) had progressive disease noted at weeks 0.5 (n ϭ 1), 12 (n ϭ 2), 16.5 (n ϭ 1), and 24 (n ϭ 1).
Tumor Marker Response. Serum pancreastatin was consistently elevated at the prestudy evaluation in 13 patients, whereas other tumor markers (pancreatic polypeptide, gastrin, glucagon, calcitonin, or neurotensin) were elevated in only a few patients at baseline (Table 1) . Tumor markers were evaluable in 10 patients, and marker levels did not correlate with Table 2 summarizes serum pancreastatin results in 10 evaluable patients. Of eight patients who showed stable disease, three patients had an 11 to 24% reduction in serum pancreastatin, whereas five patients had an increase (median increase, 44%; range, 7 to 55%) in serum pancreastatin compared with the prestudy levels. Serum pancreastatin was increased by 13 to 18% as compared with baseline in patients who showed progressive disease. Pharmacodynamic Studies. A pharmacodynamic assay was performed to correlate the degree of proteasome inhibition with tumor response or adverse events. The percentage of 20S proteasome inhibition was compared with the predose (0 hour) value obtained on the same day in each individual patient. Peripheral blood samples were evaluable in 15 of total 16 patients on the study. The mean percentage of 20S proteasome inhibition achieved in whole blood at 1 and 24 hours after (Fig. 2) . The target level of 20S proteasome inhibition was achieved in our study patients, and there was no correlation with type or degree of adverse events or clinical outcome.
Adverse Events. Bortezomib was generally well tolerated. There were no grade 4 adverse events or deaths related to the study. All of the drug-related adverse events reported in the 16 study patients are outlined in Table 3 . The worst grade experienced by individual patient was used to report the adverse events. Although the most common adverse event seen was nausea (74%), the most common grade 3 toxicities were peripheral sensory neuropathy (37%), followed by diarrhea (25%). It is noteworthy that four patients (25%) developed viral-associated infections during the study period. Three of these patients had recurrent grade 2 cold sores, whereas one patient had grade 3 conjunctivitis in absence of neutropenia. Three patients (18%) had ileus occur at the cumulative dose (mg/m 2 ) of 6, 7.5, or 10.5. All of these patients had prior laparotomy, two patients had active mesenteric carcinoid tumor, and one patient was on a stable dose of tincture of opium. Ileus resolved within 2 to 3 days of hospitalization with conservative treatment, and patients subsequently received one, three, or eight doses of bortezomib without recurrent ileus. Of the two patients who experienced grade 3 abdominal cramps, one had ileus as noted above.
A drug-related grade 2 to 3 peripheral sensory neuropathy manifested by pain, tingling, and numbness occurred in 10 patients (62%). In general, tingling and numbness were more intense in the feet and legs than in the hands, whereas neuropathic pain was mainly localized to legs and feet. All of these patients required narcotics and gabapentin for pain control. The median cumulative dose at the onset of neuropathy was 13.3 (range, 1.5 to 28.5) mg/m 2 ( Table 4) . Five of these patients had worsening of neuropathy during the off-study period at a median of 3.5 weeks (range, 3 to 9 weeks) after the last dose of bortezomib. Moreover, one patient had neuropathy symptoms starting at 3 weeks after the last of bortezomib. Grade 3 neuropathy symptoms in this patient improved to grade 2 and to grade 1 at week 12 and at week 18 after the last of bortezomib, respectively, despite subsequent treatment with etoposide and cisplatin. Although peripheral neuropathy is a common side effect of cisplatin, it is usually cumulative and progressive during the course of cisplatin chemotherapy. Thus, spontaneous improvement of neuropathy from grade 3 to grade 1 in our patient during the six cycles of cisplatin-based chemotherapy indicates its likely attribution to bortezomib. Seven of 10 patients had improvement up to grade 1 (n ϭ 5) or grade 0 (n ϭ 2) peripheral neuropathy at a median of 18 weeks (range, 2 to 76 weeks) after the last dose of bortezomib.
DISCUSSION
Given the broad spectrum of in vitro and in vivo antineoplastic activity and safety of single-agent bortezomib, we studied its efficacy in patients with metastatic neuroendocrine tumors. Despite achieving the surrogate biological end point of 20S proteasome inhibition in peripheral blood mononuclear cells obtained from 15 patients, our study failed to show any objective tumor response in this patient population. Although stable disease was noted in 11 of 16 patients (69%) at the median evaluation time of 12 weeks (range, 3 to 24 weeks) after the start of therapy, our study was not designed to evaluate progression-free survival. Given the slow growing nature of these tumors, we cannot attribute stable disease to the antitumor effect of bortezomib in our single-arm study. Given that proteasome inhibition in tumor tissue was not evaluated in our study, it is conceivable that the ineffectiveness of bortezomib may relate to an insufficient level or duration of 26S proteasome inhibition in the tumors. Although bortezomib affects the nuclear factor-B pathway, cyclin-dependent kinase inhibitors (e.g., p21, p27), or tumor suppressor (e.g., p53) proteins, it is possible that redundant pathways exist for tumor progression and survival of metastatic neuroendocrine tumors. Bortezomib was generally well tolerated at the dose and schedule used in our study. Similar to previously reported studies, the most common adverse events in this study included gastrointestinal, neurologic, constitutional, and hematologic. However, we observed a higher (37 versus 12%) incidence of grade 3 peripheral sensory neuropathy in our chemo-naïve patients compared with the phase II trial of bortezomib in multiple myeloma (16) . It is unclear if grade 3 pain in limb reported in 7% of their study patients was neuropathic pain. Given that 86% of patients in the reported myeloma study had prior thalidomide (and likely Vinca alkaloids), it is possible that an attribution of neuropathy to bortezomib might have been difficult. Although the median duration of therapy administered in both studies was roughly similar (12 versus 15 weeks), the dose of bortezomib was higher (1.5 versus 1.3 mg/m 2 /dose) in our study. Thus, it is possible that the higher dose may account for the higher incidence of neuropathy seen in our study. A recently reported phase II study used a dose and schedule similar to our study and reported only 9% grade 3 peripheral neuropathy but 47% incidence for all grades of neuropathy (25) . Although we did not evaluate predisposing factors for neurop- athy in a prospective manner, no obvious risk factors (such as diabetes mellitus, concomitant or prior neurotoxic medications, or B12 deficiency) were found in our patients. Peripheral sensory neuropathy was generally dose related, cumulative, and reversible up to less than or equal to grade 1 ( Table  4 ). The median time in improvement or resolution of neuropathy was 18 weeks (range, 2 to 76 weeks) after the last dose of bortezomib. However, patients were not required to follow-up at the specific intervals during the off-study period. The clinical pattern seen in our patients with peripheral neuropathy was most consistent with small-fiber painful sensory neuropathy where A-␦ (small myelinated) and nociceptive C (unmyelinated) nerve fibers are affected. With the striking association of peripheral neuropathy with bortezomib, it is possible that the ileus, abdominal cramps, syncope, dizziness, and orthostatic hypotension seen in seven of our patients (43%) could be a result of bortezomib-related autonomic neuropathy. Six of seven patients who developed such symptoms also developed grade 2 to 3 peripheral neuropathy during the course of their therapy. Although existing predisposing factors (e.g., prior laparotomy, narcotic use, or active bowel carcinoid tumor) could explain the occurrence of ileus in three of our patients (18%), possible association of ileus with bortezomib cannot be excluded. Interestingly, there were eight patients on the study who had prior laparotomy for tumor debulking who did not develop ileus. The high incidence of nausea and vomiting seen our study suggests that patients might benefit from prophylactic antiemetic therapy. Although the given patient population could have diarrhea because of carcinoid syndrome, the baseline symptoms were taken into consideration in grading diarrhea, and no simultaneous worsening of other carcinoid syndrome symptoms was seen. Hematologic toxicity was of short duration alleviating the need for transfusion or growth factor support. We also question whether bortezomib administration might be associated with viral reactivation given that 25% of our patients had either cold sores or conjunctivitis in the absence of neutropenia. Of note, we did not observe any of the electrolyte abnormalities seen in phase I studies.
In conclusion, single-agent bortezomib does not have activity in patients with metastatic neuroendocrine tumors. Bortezomib is safe at the schedule and dose used in our study, with the most significant clinical adverse event being a peripheral sensory neuropathy. The detailed evaluation of bortezomibassociated neurotoxicity, including autonomic neuropathy and value of prophylactic strategies, merits future investigation. These studies will be particularly helpful because this agent may be used with other neurotoxic agents in the future. Furthermore, with growing preclinical data demonstrating synergism between bortezomib and cytotoxic chemotherapy (26 -30) , future studies should evaluate bortezomib in combination with chemotherapy in solid tumors but caution should be taken in combining chemotherapy that may have overlapping gastrointestinal or neurologic toxicity.
